Form 4: TransMedics Director Sells Shares
Statement of Changes in Beneficial Ownership
Thomas J. Gunderson, a Director at TransMedics Group, Inc., reported a transaction involving the sale of common stock.
Summary
- Thomas J. Gunderson, a Director of TransMedics Group, Inc., reported a transaction on June 15, 2026.
- He acquired 19,285 shares of common stock at a price of $2.21 per share.
- He also disposed of 9,624 shares of common stock at a price of $75.06 per share.
- Following these transactions, Gunderson beneficially owns 16,642 shares of common stock directly.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral filing, as it primarily reports on routine insider stock transactions (option exercise and sale) without providing new financial performance data or strategic outlook.
Positives
- Acquisition of 19,285 shares of common stock at a favorable price of $2.21 per share, potentially indicating a belief in the company's future value or a planned exercise of options.
- The transaction code 'M' for acquisition and 'S' for sale suggests a mix of planned and executed events.
Negatives
- Disposal of 9,624 shares of common stock at a significantly higher price of $75.06 per share, which could indicate a profit-taking action by a company insider.
Future Outlook
The filing does not contain forward-looking statements or guidance.
Industry Context
StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions, providing transparency into the buying and selling activities of company directors and officers. These transactions can offer insights into insider confidence but should be analyzed in conjunction with other financial and operational data.
Stakeholder Impact
- Shareholders may observe this transaction as an insider taking profits, which could be interpreted neutrally or slightly negatively depending on the overall market sentiment and company performance.
Key Dates
| Date | Description |
|---|---|
| 08/01/2016 | Date stock options were granted. |
| 06/15/2026 | Date of the reported transaction (acquisition and disposal of shares). |
| 06/17/2026 | Date the statement was signed by the attorney-in-fact. |
Keywords
Form 4, SEC Filing, Insider Transaction, Stock Sale, Stock Option Exercise, TransMedics Group, TMDX, Director Transaction
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.